Asset Management One Co. Ltd. Purchases 602 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Asset Management One Co. Ltd. raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,913 shares of the medical equipment provider’s stock after acquiring an additional 602 shares during the period. Asset Management One Co. Ltd.’s holdings in Zimmer Biomet were worth $8,754,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in ZBH. Exchange Traded Concepts LLC lifted its stake in Zimmer Biomet by 3,043.1% in the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after acquiring an additional 1,552 shares during the period. NBC Securities Inc. purchased a new stake in Zimmer Biomet in the third quarter worth about $105,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Zimmer Biomet by 1.5% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock worth $2,400,000 after acquiring an additional 337 shares during the period. Blue Trust Inc. lifted its stake in Zimmer Biomet by 165.3% in the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after acquiring an additional 1,071 shares during the period. Finally, Border to Coast Pensions Partnership Ltd lifted its stake in Zimmer Biomet by 4.5% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock worth $16,711,000 after acquiring an additional 6,623 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.6 %

Shares of NYSE:ZBH opened at $100.52 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The firm has a market capitalization of $20.01 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The firm’s 50-day moving average is $106.34 and its two-hundred day moving average is $107.67. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays decreased their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.